Normal Saline Versus Ringer's Lactate for Initial Fluid Resuscitation in Sepsis
Key facts
- Who runs it
- Egemen Yildiz
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 88 people, planned
- Started
- Nov 2025
- Expected to end
- Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ringer's Lactate
- Normal Saline (0.9% Sodium Chloride)
- Record updated
- 21 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Adult male or female patients (≥18 years of age) presenting to the emergency department
- Diagnosed or suspected sepsis secondary to an infectious cause
- Provision of written informed consent by the patient, or if the patient is unable to consent, by a first-degree relative or legally authorized representative
Who cannot take part
- Patients who are receiving cardiopulmonary resuscitation (CPR) or who require endotracheal intubation at the time of presentation
- Cases in which the treating physician anticipates that fluid therapy might be delayed due to study participation
- Patients with severe volume depletion unrelated to sepsis (e.g., diabetic ketoacidosis, burns, or active gastrointestinal bleeding)
- Patients with hypotension that is not related to sepsis (e.g., active hemorrhage or intracranial bleeding)
- Patients with clinical signs of pulmonary edema or congestive heart failure
- Cases in which the treating physician determines that one isotonic crystalloid (Ringer's lactate or 0.9% NaCl) is clearly superior to the other due to clinical condition or comorbidities
- Severe renal failure with oliguria or anuria
- Decompensated heart failure
- Conditions associated with impaired lactate metabolism, such as lactic acidosis, severe liver failure, and cirrhosis with ascites
- Patients with severe hyperkalemia (serum potassium level of at least 6.5 mmol/L with ECG changes)
- Known hypersensitivity to sodium lactate
- Age under 18 years old
- Pregnant women
- Informed consent was not obtained from the patient or their first-degree relative/legal guardian
- Patients requiring immediate hospital or ICU admission before completion of initial emergency department resuscitation
- Patients with sepsis sources requiring urgent invasive intervention known to directly affect mortality (e.g., an undrainable abscess or osteomyelitis); Additional exclusion criteria based on the contraindications listed in the Ringer's lactate product information:,
- Extracellular hyperhydration or hypervolemia
- Hypercalcemia
- Metabolic alkalosis or severe metabolic acidosis
- Current use of digitalis preparations (e.g., digoxin)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sepsis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to determine if the type of intravenous fluid used for initial resuscitation affects the short-term outcomes of adult patients with sepsis who are treated in the emergency department.
Read full original descriptionShow less
The main questions it aims to answer are:
Does using Ringer's lactate instead of 0.9% sodium chloride (normal saline) reduce 24-hour mortality in patients with sepsis?
Does the type of fluid influence other short-term outcomes, such as the need for vasopressors, mechanical ventilation, hemodialysis, and length of hospital stay?
Researchers will compare two groups of participants:
* The Ringer's lactate group (intervention group) * The 0.9% sodium chloride group (control group).
Participants will:
* Receive either Ringer's lactate or normal saline for initial fluid resuscitation as part of standard sepsis care. * They will be observed for 24 hours to assess survival and other early outcomes.
The 2 groups in the trial
- Ringer's Lactate GroupTreatment being tested
Eligible participants in this group will receive Ringer's lactate solution as the initial intravenous fluid for resuscitating sepsis. This will be administered through a peripheral intravenous line at a rate of 1000 ml over 30-60 minutes, as determined by the attending physician and the patient's clinical condition. All other treatments will follow standard sepsis care protocols.
Treatment: Ringer's Lactate
- Normal Saline GroupExisting treatment, for comparison
Eligible participants in this arm will receive 0.9% sodium chloride (normal saline) as the initial intravenous fluid for resuscitation in sepsis. This will be administered through a peripheral intravenous line at a rate of 1000 ml over 30-60 minutes, as determined by the attending physician and the patient's clinical condition. All other treatments will follow standard sepsis care protocols.
Treatment: Normal Saline (0.9% Sodium Chloride)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Single-Center, Randomized Controlled Trial Comparing Normal Saline and Ringer's Lactate for Initial Fluid Resuscitation in Adult Patients With Sepsis in the Emergency Department
- Criteria questions
- Built from NCT07240701, who can take part
- Record updated
- 21 November 2025